Clinical trial
Growth and Development Study of Alglucosidase Alfa
NCT00486889 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00486889 |
|---|---|
| Title | Growth and Development Study of Alglucosidase Alfa |
| Official title | A Long-term Study to Evaluate Growth and Development Outcomes in Patients With Infantile-Onset Pompe Disease Who Are Receiving Alglucosidase Alfa |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency Disease |
| Intervention type | Biological |
| Interventions | alglucosidase alfa |
| Enrollment | 12 |
| Start date | Aug 26, 2008 |
| Primary completion | Nov 23, 2021 |
| Completion | Nov 23, 2021 |
| First posted | Jun 15, 2007 |
| Last update posted | Aug 26, 2022 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: